Aziyo Biologics, Inc.

20 articles with Aziyo Biologics, Inc.

• Aziyo Biologics Reports Third Quarter 2020 Financial Results

  11/19/2020

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and nine months ended September 30, 2020.

• Aziyo Biologics to Participate in the Piper 32nd Annual Virtual Healthcare Conference

  11/17/2020

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Piper Virtual Healthcare Conference

• Aziyo Biologics Awarded Breakthrough Technology Contract with Premier Inc.

  11/12/2020

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, has been awarded a group purchasing agreement with Premier Inc., for Premier’s Technology Breakthroughs Program.

• Aziyo Biologics to Report Third Quarter 2020 Financial Results on Thursday, November 19, 2020

  11/5/2020

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it plans to release its third quarter earnings results after market close on Thursday, November 19, 2020.

• Aziyo Biologics Announces Pricing of Initial Public Offering

  10/7/2020

  Aziyo Biologics, Inc. (Nasdaq: AZYO) today announced the pricing of its initial public offering of 2,941,176 shares of common stock, consisting of 2,205,882 shares of Class A common stock and 735,294 shares of Class B common stock,

• Aziyo Biologics Announces Appointment of Chief Financial Officer

  9/28/2020

  Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today that Matthew Ferguson has been appointed Chief Financial Officer (CFO), effective immediately. “We are extremely pleased to welcome a strong leader like Matt to the Aziyo team at such an important point in our business’ g

• Aziyo Biologics Announces New Appointments to Board of Directors

  9/21/2020

  Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today that Maybelle Jordan, Vice President of Business Development of Biomerix Corporation, and Brigid Makes, former Senior Vice President and Chief Financial Officer of Miramar Labs, have joined its board of directors. Maybell

• Aziyo Biologics Announces Launch of OsteGro® VExpands Regenerative Medicine Product Portfolio and Leverages Proprietary Processing Platform to Protect and Preserve Native Bone Cells

  6/29/2020

  Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage, regenerative medicine company creating the next generation of differentiated products to improve outcomes in patients undergoing surgery, announced today the launch of its newest OsteGro® family product, OsteGro V,

• Aziyo Announces Publication of RECON Study of Pericardial Reconstruction Using ProxiCor

  4/10/2019

  Prospective Study of 1,420 Patients Showed Statistically Significant Reduction in Post-Operative Complications and 30-Day Hospital Readmission Rates

• RTI Surgical® and Aziyo® Biologics Announce Exclusive Agreement to Distribute ViBone® for Spine and Other Orthopedic Procedures

  8/2/2018

  Agreement will expand availability of ViBone, a next generation cellular bone matrix product

• Aziyo Partners with SurGenTec for Minimally Invasive Bone Graft Delivery

  7/13/2018

  ​ViBone viable bone matrix in GraftGun to be marketed for minimally invasive spine and orthopedic surgery

• Ronald Lloyd Announced as New President and CEO of Aziyo Biologics

  6/4/2018

  Seasoned leader brings a wealth of experience in commercial and business development

• Aziyo Announces CanGaroo Strategic Co-Distribution Agreement with BIOTRONIK US

  4/19/2018

  Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced that it has entered into a US co-distribution agreement for its CanGaroo® Bio Envelope with BIOTRONIK, Inc., a global leader in cardio- and endovascular medical technology.

• Aziyo Biologics Expands Bone Repair Franchise with Launch of OsteGro

  3/22/2018

  Innovative processing and delivery characteristics provide significant improvement versus other available products

• Aziyo and Cook Biotech Announce Further Expansion of the Bio Envelope Franchise into Additional Markets

  2/16/2018

  Aziyo Biologics, Inc. and Cook Biotech Inc. today announced the expansion of the Aziyo Bio Envelope franchise by entering into additional exclusive global license agreements expanding the applications for the Bio Envelope product into the field of neuromodulation.

• Aziyo Presents Positive Initial Data From Clinical Study of Biologic Extracellular Matrix Scaffold for Femoral Arterial Reconstruction

  11/15/2017

  There were no device-related adverse events or infections and primary patency was maintained in 97.6% of procedures.

• Aziyo Launches CanGaroo Bio Envelope for Subcutaneous Implantable Cardioverter-Defibrillators

  11/6/2017

• Aziyo Biologics Completes Enrollment In Prospective Post Market Study Of Cangaroo ECM Envelope

  8/29/2017

• Aziyo Biologics Banks Some Cash And Former Osiris Exec As Its New CEO

  6/15/2017

• Ligand Announces Aziyo Biologics Acquires Commercial Products From Partner CorMatrix Cardiovascular

  6/1/2017